Next Meeting
November 11, 2017

The Union League Club
of Philadelphia

7 am to 12 noon


Dear Members of the Philadelphia Endocrine Society,

I would like to let you know of two protocols for phase III trials of new medications to treat Cushing’s that are currently open for enrollment at the University of Pennsylvania.

LCI699 (Novartis) is a potent inhibitor of adrenal steroidogenesis for treatment of Cushing’s disease. In a phase II trial, it decreased 24-urine cortisol to normal in 90% of patients. To qualify, patients must have documented Cushing’s disease (not ectopic ACTH or adrenal adenoma).

COR-003 (Cortendo) is also an inhibitor of adrenal steroidogenesis. It is an isomer of ketoconazole that appears to be less likely to cause liver toxicity. Patients who have ectopic ACTH, as well as Cushing’s disease, would qualify for this protocol. 

If you have patients you want to be considered for any of these protocols, or if you have general questions, please email or call Eileen Markmann (Eileen, 215-350-0364) or me, (, 215-898-0208). 

Peter Snyder
Dear Members of the Philadelphia Endocrine Society,

We are currently recruiting for an NIH-funded study of older individuals with persistent subclinical hypothyroidism and we need help finding participants.

We are studying the mechanism behind the age-related increase in TSH levels. We will be administering LT4 and LT3 in a cross-over design, and TRH stimulation testing will be performed.

Patients aged 70 years or older who have a TSH between 4.5-19.9 mU/L who are not already taking thyroid hormone are eligible.

Please email or call Lakshmi Kannan (; 215-746-1151), Terry Scattergood (; 215-898-5664) or me (; 215-573-5359) with any potential participants or questions about the study.

Anne Cappola, MD, ScM

​Thyroid Cancer 2017: New Advances in Diagnosis and Treatment
Sidney Kimmel Cancer Center at Thomas Jefferson University
Friday, November 10, 2017
The course will evaluate and present the recent advances in diagnostic and therapeutic approaches to Thyroid Cancer and Thyroid Nodular Disease that have altered traditional management paradigms.
Registration and Agenda